Fertility-sparing treatment for endometrial cancer based on molecular type
Treatments studied
Part of Cancer, Women’s health & pregnancy clinical trials.
This trial tests a tailored approach to preserve fertility in women with early-stage endometrial cancer, using medications like hormones and immunotherapy based on the tumor's molecular subtype. It aims to avoid hysterectomy and keep the uterus intact.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 45 years old
- You strongly wish to preserve your fertility or keep your uterus
- You have newly diagnosed or recurrent endometrial cancer that is confined to the uterus
- Your tumor has a specific molecular subtype (POLE-mutant, MSI-H, or NSMP) and not the p53-abnormal type
- You must have normal blood counts, liver and kidney function, a good performance status (KPS ≥ 90)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of an immunotherapy drug (TQB2450) with a hormone treatment (progestin) for patients with a specific type of early-stage uterine cancer who wish to preserve their ability to have children. The goal is to see if this approach is safe and effective.
This trial tests a combination of an immunotherapy drug (PD-1 inhibitor) and progesterone hormone therapy to treat early-stage, MMR-deficient endometrial cancer while preserving fertility. It may help young women who want to keep the option to have children in the future.
This trial tests a new study medicine called PF-08634404 when combined with standard chemotherapy for people with advanced or recurrent endometrial cancer that is MMR-proficient (meaning the DNA repair system is working normally). The goal is to see if adding this medicine helps shrink or control the cancer better than chemotherapy alone.
This trial compares two ways to treat endometrial cancer after surgery: a new option of just radiotherapy plus a daily hormone tablet (progestin) versus the current standard of radiotherapy plus chemotherapy. It aims to see if the new option works just as well with fewer side effects.
This trial tests whether adding the weight-loss drug orlistat to standard hormone therapy can help shrink early-stage endometrial cancer or precancerous changes, so you can avoid having your uterus removed and still try for a baby later.
This study looks at whether a hormone-releasing IUD (LNG-IUS) can treat early-stage endometrial cancer or very early abnormal cell growth while helping you keep the option for future pregnancy. It aims to see how well the treatment works and how it affects fertility-related outcomes.
Hear when a new Endometrial Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.